ClinicalTrials.gg
CompletedNCT07404137Updated Apr 13, 2026

A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food

A Phase 1 interventional study of Zibotentan/Dapagliflozin FDC in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic — 15 open to participants now, 21 under way, 7 of them phase 3. dapagliflozin · Renal Insufficiency, Chronic.

Enrollment
36th of 40
26 · median 100
Started
2026
with 5 others
Phase 1
2 of 40
none open now
Registered
35th of 40
by date
Lead sponsor
9 of 40
AstraZeneca

Among the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, this one is the 36th largest by enrollment, is one of 6 that started in 2026, is one of 2 in phase 1, and was the 35th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

15 of the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the concentrations of zibotentan and dapagliflozin in blood when given with and without food in healthy participants.

Read the detailed description

This is a Phase I, open-label, randomized, 2-period, 2-treatment, crossover study in healthy participants.

This study will measure the impact of food on the pharmacokinetics (PK) of combined zibotentan/dapagliflozin for the to be marketed fixed-dose combination (FDC) formulation (study intervention).

The study will comprise of, (i) A screening period (ii) 2 treatment periods (iii) A final follow-up visit.

All participants will receive a single dose of the study intervention once under fasted condition (Treatment A) and once under fed condition (Treatment B).

03

Conditions studied

  • Healthy Participants

Keywords

  • Chronic kidney disease
  • Pharmacokinetics
  • Food effect
  • Fixed-dose combination
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female of non-. Participants with suitable veins for cannulation or repeated venipuncture.
  • Have a (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg (inclusive) at Screening.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma.
  • Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results or other laboratory values or vital signs.
  • Any positive result on screening for serum surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), virus (HCV) antibody, or (HIV) (Type 1 and 2) antibodies.
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
  • History or ongoing allergy/, to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i- eg, dapagliflozin, empagliflozin), or zibotentan or other Endothelin Receptor Antagonist (ERAs- eg, ambrisentan, atrasentan,bosentan), or any of the in the zibotentan/dapagliflozin tablets.
  • Participants who have previously received zibotentan.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Treatment AB

    Participants will receive single dose of Zibotentan/Dapagliflozin FDC after an overnight fast of at least 10 hours (Treatment A). After a washout period, participants will receive another single dose of Zibotentan/Dapagliflozin FDC 30 minutes after having a high-fat, high-calorie standardized meal (Treatment B).

    Drug: Zibotentan/Dapagliflozin FDC

  • Experimental
    Treatment BA

    Participants will receive single dose of Zibotentan/Dapagliflozin FDC 30 minutes after having a high-fat high-calorie standardized meal (Treatment B). After a washout period, participants will receive another single dose of Zibotentan/Dapagliflozin FDC after an overnight fast of at least 10 hours (Treatment A).

    Drug: Zibotentan/Dapagliflozin FDC

Interventions

  • DrugZibotentan/Dapagliflozin FDC

    Drug pages: ZD4054 · Dapagliflozin

    Zibotentan/Dapagliflozin FDC will be administered as an oral tablet.

06

What researchers measure

Primary outcomes

  1. Area under concentration-time curve from time 0 to infinity (AUCinf)

    To investigate the effect of a high fat, high calorie meal, in comparison to fasting conditions, on the PK of zibotentan/dapagliflozin FDC after a single oral dose in healthy participants.

    Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To investigate the effect of a high fat, high calorie meal, in comparison to fasting conditions, on the PK of zibotentan/dapagliflozin FDC after a single oral dose in healthy participants.

    Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods

  3. Maximum observed drug concentration (Cmax)

    To investigate the effect of a high fat, high calorie meal, in comparison to fasting conditions, on the PK of zibotentan/dapagliflozin FDC after a single oral dose in healthy participants.

    Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods

Secondary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To further assess the safety and tolerability of single doses of zibotentan/dapagliflozin FDC in healthy participants.

    Time frame: Up to end of study visit, for a total of approximately 5 weeks

  2. Apparent total body clearance (CL/F)

    To further evaluate the PK of zibotentan/dapagliflozin FDC after a single oral dose in healthy participants.

    Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods

  3. Apparent volume of distribution based on the terminal phase (Vz/F)

    To further evaluate the PK of zibotentan/dapagliflozin FDC after a single oral dose in healthy participants.

    Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods

  4. Time to reach maximum observed concentration (tmax)

    To further evaluate the PK of zibotentan/dapagliflozin FDC after a single oral dose in healthy participants.

    Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods

  5. Terminal elimination half-life (t½λz)

    To further evaluate the PK of zibotentan/dapagliflozin FDC after a single oral dose in healthy participants.

    Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods

07

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Apr 2026, 1 month.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 11, 2026
StartActual
Feb 16, 2026
Primary completionActual
Apr 2, 2026
CompletionActual
Apr 2, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07404137
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Feb 16, 2026
Primary completion
Apr 2, 2026
Completion
Apr 2, 2026
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ZD4054 · Dapagliflozin

Start the discussion